Issi Rozen is Chief Business Officer at the Broad Institute of MIT and Harvard, responsible for partnering with the life sciences industry and venture investors and developing innovative scientific and business collaborations.
He is also responsible for initiating and establishing new ventures around novel research projects and for licensing the institute’s intellectual property portfolio.
He joined the Broad in 2011 after a career in the pharmaceutical industry. Before joining the Broad Institute, Rozen was Director of Corporate Development at Resolvyx Pharmaceuticals, a venture-backed biotech start-up, where he led the business development efforts.
Before that, he headed the business analysis group at EMD Serono where he was responsible for evaluations of in-licensing and M&A opportunities as well as commercial analytics and forecasting for pipeline and commercial products.
Issi is also a co-founder of a number of Boston-area biotech start-ups and is an accomplished jazz guitarist.
He earned his M.B.A. at MIT’s Sloan School of Management.